(NASDAQ: AVTX) Avalo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.88%.
Avalo Therapeutics's earnings in 2026 is -$100,333,000.On average, 16 Wall Street analysts forecast AVTX's earnings for 2026 to be -$134,949,141, with the lowest AVTX earnings forecast at -$185,527,584, and the highest AVTX earnings forecast at -$95,166,415. On average, 16 Wall Street analysts forecast AVTX's earnings for 2027 to be -$143,637,200, with the lowest AVTX earnings forecast at -$215,485,296, and the highest AVTX earnings forecast at -$82,214,773.
In 2028, AVTX is forecast to generate -$168,564,418 in earnings, with the lowest earnings forecast at -$237,559,399 and the highest earnings forecast at -$113,749,207.